Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-benefits of Co-delivery of Long-acting Antiretrovirals and Contraceptives
NCT05044962Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cabotegravir + rilpivirine in human immunodeficiency virus infection (HIV) (7 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Hormone concentrations with cabotegravir/rilpivirine use at 24 weeks and Number of participants with HIV viral suppression at 48 weeks. Started Nov 2021; status: recruiting.
02
Drugs
cabotegravir + rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05044962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044962.